Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients

NCT00057382 is registered in ClinicalTrials.gov with Tularik as lead sponsor.

NCT NCT00057382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00057382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
Lead sponsor
Tularik
Phase
Phase 2/3
Overall status
Terminated
Start date
March 31, 2003
Completion date
Not reported
Enrollment
750
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma